Akorn (AKRX) Tops Q3 EPS by 2c
- Nasdaq outshines Wall St peers on tech boost, earnings glee
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
BofA/Merrill Lynch Downgrades Akorn (AKRX) to Underperform
November 7, 2016 7:13 AM ESTBofA/Merrill Lynch downgraded Akorn (NASDAQ: AKRX) from Buy to Underperform with a price target of $22.00.
For an analyst ratings summary and ratings history on Akorn click here. For more ratings news on Akorn click here.
Shares of Akorn closed at $19.68 yesterday.
... MoreJefferies Cuts Price Target on Akorn (AKRX) to $24; Reiterates Buy
November 4, 2016 9:52 AM EDTJefferies maintained a Buy rating on Akorn (NASDAQ: AKRX), and cut the price target to $24.00 (from $35.00), following the company's 3Q earnings report. Jefferies lowered estimates as re-inspection issues create more uncertainty. Assuming a 6 month delay expected revenues from pipeline products... More
RBC Capital Downgrades Akorn (AKRX) to Sector Perform
November 4, 2016 6:13 AM EDTRBC Capital downgraded Akorn (NASDAQ: AKRX) from Outperform to Sector Perform with a price target of $24.00 (from $37.00) on a higher risk profile and challenged P&L visibility.
Analyst Randall Stanicky commented, "As previewed on Monday, we entered 3Q looking for better clarity around FDA... More